Press Releases

IGY Life Sciences  announced it will be collaborating with clinical data and regulatory experts, MMS Holdings (MMS), to further the development of IgY-110, an anti-CoV-2 therapeutic antibody with a focus on a nasal spray application. This novel approach of an IgY antibody in a nasal spray will be complementary to any vaccine developed. Currently in the preclinical stage, the new antibody is being tested at the Canadian Government National Microbiology Lab in Winnipeg, Manitoba

Junshi Biosciences, a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, today announced that the first healthy volunteer has been dosed in the Phase I clinical study of JS016 at Huashan Hospital Affiliated to Fudan University in China. JS016 is the first SARS-CoV-2 neutralizing antibody to enter clinical trials in China. Junshi and Eli Lilly and Company are collaborating to co-develop JS016 globally, with Jun

Polyneuron Pharmaceuticals AG, a clinical stage developer of a new class of biodegradable glycopolymers for the treatment of autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to PN?1007 (PPSGG) in the treatment of anti-MAG neuropathy, a disabling, chronic disorder of the peripheral nervous system. Orphan designation is granted to advance the development of safe and effective therapies for the treatment of rare diseases or

MOBILion Systems, Inc. is showcasing its first ion mobility separations product to the biopharma drug development and academic research markets, with data from its first beta users, during the American Society for Mass Spectrometry’s (ASMS) 2020 virtual conference. MOBILion Systems is commercializing a patented ion mobility separations technology, called Structures for Lossless Ion Manipulation (SLIMTM), to efficiently separate, identify and analyze the most challenging, clini

Research Corporation Technologies, Inc. (RCT) announced today that it has acquired and invested growth capital into Translational Drug Development (TD2), the leading fully integrated precision oncology medicine development organization. TD2 provides end-to-end solutions, including translational preclinical services; regulatory strategic guidance, planning and document submission services; and clinical trial design and execution for innovative oncology-focused companies. TD2, based i

Espero BioPharma, Inc., a pharmaceutical company focused on the development of therapeutics for unmet needs in thrombosis and cardiac rhythm control, today expanded a collaborative partnering effort for its lead product candidate tecarfarin. Tecarfarin is a Phase III-ready, vitamin K antagonist, taken once a day as an oral anticoagulant like warfarin, but targets a metabolic pathway that is distinct from the one targeted by the most commonly prescribed anticoagulants. In 2019, the F

Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious illnesses, is pleased to announce that the Food and Drug Administration (FDA) in the United States has granted the designation of disease rare pediatric (or RPDD according to the English acronym) with 67 Cu-SARTATE ™, a therapy intended for the clinical treatment of neuroblastoma. The FDA defines as "rare pediatric disease" (or RPD according to the English acronym) a serious or

Marinomed Biotech AG, a globally operating biopharmaceutical company based in Vienna, is entering the Italian market for cold remedies via its Carragelose® products. This market is the third-largest of its kind in Europe. New marketing partner Fidia Farmaceutici Spa is set to offer Carragelose®-based nasal sprays on the Italian market as of autumn 2020. Oral Carragelose® products such as throat sprays and lozenges will also become available to more than 60 million Italians in the

Treadwell Therapeutics, a clinical-stage biotechnology company developing novel therapeutics for highly aggressive cancers, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application to evaluate its third therapeutic candidate, CFI-402411, an oral, first-in-class inhibitor of hematopoietic progenitor kinase 1 (HPK1) in patients with solid tumors as a monotherapy or in combination with PD1 pathway blockade. In addition, Treadwel

CytoSMART Technologies today announced the launch of a new live-cell imaging system. The CytoSMART Lux2 Duo Kit offers a straightforward, cost-effective solution for researchers carrying out immediate side-by-side comparisons between cell cultures. Said Jan-Willem van Bree, CTO at CytoSMART Technologies “Employing this two camera mini live cell imaging system is especially useful for stem cell research. Researchers can use the remote functionality of the CytoSMART cloud to gai